Physician profile
Maureen E Mccarthy
NPI 1902221443
$7,362.10
in general payments reported to CMS, 2019-2025
26 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $1,212 · 2023: $1,659 · 2024: $1,769 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,557 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,556.82 |
| Education | $289.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,482.46 | 2021-2025 | |
| Janssen Biotech, INC. | $993.21 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $934.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $762.30 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $362.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $336.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $330.08 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $309.66 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $272.61 | 2021-2024 | Adbry |
| Ucb, INC. | $246.70 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $243.33 | 2021-2022 | |
| Pfizer INC. | $207.29 | 2021-2025 | |
| Incyte Corporation | $192.93 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $97.12 | 2021-2025 | Nemluvio, Aklief |
| Vyne Pharmaceuticals INC. | $82.68 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.94 | 2023-2024 | Cyltezo, Spevigo |
| Arcutis Biotherapeutics, INC. | $64.47 | 2023-2024 | Zoryve |
| Almirall LLC | $59.76 | 2022-2025 | Klisyri, Seysara |
| Verrica Pharmaceuticals INC. | $48.40 | 2024 | Ycanth |
| Amgen INC. | $42.87 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.67 | 2021-2024 | Siliq |
| Dermavant Sciences, INC. | $29.76 | 2024 | Vtama |
| Journey Medical Corporation | $27.48 | 2023 | |
| Organon LLC | $22.07 | 2024-2025 | |
| Sandoz INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.